|
|
Volumn 20, Issue 7, 2014, Pages 877-881
|
|
Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis
a
b
c
d
d
d
d
e
f
g
|
|
Author keywords
Disease modifying therapy; Fingolimod; Long term; Phase 2; Relapsing remitting multiple sclerosis; Sphingosine 1 phosphate receptor modulator
|
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
FINGOLIMOD;
PLACEBO;
IMMUNOSUPPRESSIVE AGENT;
ANXIETY;
ARTHRALGIA;
ARTICLE;
ASTHMA;
BACKACHE;
BRADYCARDIA;
BRAIN SIZE;
BRONCHITIS;
CHOLELITHIASIS;
COUGHING;
DEPRESSION;
DIARRHEA;
DISABILITY;
DISEASE COURSE;
DRUG DOSE COMPARISON;
DRUG WITHDRAWAL;
EXTRASYSTOLE;
FATIGUE;
FOLLOW UP;
HEADACHE;
HEART PALPITATION;
HUMAN;
HYPERTENSION;
INFLUENZA;
INSOMNIA;
LEUKOPENIA;
LYMPHOCYTOPENIA;
MAJOR CLINICAL STUDY;
MELANOMA;
MULTIPLE SCLEROSIS;
NAUSEA;
NUCLEAR MAGNETIC RESONANCE IMAGING;
OUTCOME ASSESSMENT;
PHASE 2 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RECURRENCE RISK;
RETINA MACULA EDEMA;
RHINOPHARYNGITIS;
RISK ASSESSMENT;
SIDE EFFECT;
THORAX PAIN;
TRAFFIC ACCIDENT;
UPPER RESPIRATORY TRACT INFECTION;
ANXIETY DISORDER;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG DOSE REDUCTION;
DRUG FATALITY;
HEART VENTRICLE EXTRASYSTOLE;
INTENTION TO TREAT ANALYSIS;
LONGITUDINAL STUDY;
MACULAR EDEMA;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
POPULATION RESEARCH;
TREATMENT OUTCOME;
UNSPECIFIED SIDE EFFECT;
CLINICAL TRIAL;
DISEASE EXACERBATION;
IMMUNOLOGY;
ORAL DRUG ADMINISTRATION;
TIME FACTOR;
ADMINISTRATION, ORAL;
DISABILITY EVALUATION;
DISEASE PROGRESSION;
DOUBLE-BLIND METHOD;
FINGOLIMOD HYDROCHLORIDE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MAGNETIC RESONANCE IMAGING;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 84902124003
PISSN: 13524585
EISSN: 14770970
Source Type: Journal
DOI: 10.1177/1352458513513059 Document Type: Article |
|
Times cited : (18)
|
|
References (10)
|
